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G E N E T I C S
FAN1-MLH1 interaction affects repair of DNA 
interstrand cross-links and slipped-CAG/CTG repeats
Antonio Porro1†, Mohiuddin Mohiuddin2†, Christina Zurfluh1, Vincent Spegg3, Jingqi Dai4, 
Florence Iehl4, Virginie Ropars4, Giulio Collotta1, Keri M. Fishwick1, Nour L. Mozaffari1, 
Raphaël Guérois4, Josef Jiricny1, Matthias Altmeyer3, Jean-Baptiste Charbonnier4,  
Christopher E. Pearson2,5*, Alessandro A. Sartori1*
FAN1, a DNA structure-specific nuclease, interacts with MLH1, but the repair pathways in which this complex acts 
are unknown. FAN1 processes DNA interstrand crosslinks (ICLs) and FAN1 variants are modifiers of the neurode-
generative Huntington’s disease (HD), presumably by regulating HD-causing CAG repeat expansions. Here, we 
identify specific amino acid residues in two adjacent FAN1 motifs that are critical for MLH1 binding. Disruption 
of the FAN1-MLH1 interaction confers cellular hypersensitivity to ICL damage and defective repair of CAG/CTG 
slip-outs, intermediates of repeat expansion mutations. FAN1-S126 phosphorylation, which hinders FAN1-MLH1 
association, is cell cycle–regulated by cyclin-dependent kinase activity and attenuated upon ICL induction. Our 
data highlight the FAN1-MLH1 complex as a phosphorylation-regulated determinant of ICL response and repeat 
stability, opening novel paths to modify cancer and neurodegeneration.
INTRODUCTION
In 2010, four different research groups independently reported the 
identification of human FAN1 as a DNA repair nuclease required 
for interstrand cross-link (ICL) repair (1–4). Further studies revealed 
interactions between FAN1 and mismatch repair (MMR) proteins 
of the MutL family (MLH1, PMS2, and MLH3) (2, 4, 5). However, 
the relevance and functional implications of the FAN1-MutL com-
plexes for genome stability remains to be determined.
MMR proteins and, more recently, FAN1 have been implicated 
in disease-associated trinucleotide repeat instability. Expansions of 
repeats are associated with a growing number of neurological disor-
ders, including Huntington’s disease (HD), a dominantly inherited 
condition caused by an expanded CAG repeat in the huntingtin 
(HTT) gene (6, 7). Both MLH1 and FAN1 were identified as HD 
age-of-onset modifier genes in genome-wide association studies of 
HD individuals (8–10). Previous findings demonstrated that Mlh1 
and Mlh3 are essential for somatic CAG expansions in HD knock-
in mice, implicating MutLg (MLH1-MLH3) as one of the drivers of 
HD pathogenesis (11, 12). In contrast, FAN1 was proposed to have a 
protective role in HD progression by minimizing ongoing HTT CAG 
expansion mutations in cultured mitotic and postmitotic neuronally 
differentiated HD patient cells (10, 13). Notably, the enhanced so-
matic CAG expansions of the Htt CAG tract in tissues (brain and 
liver) of Fan1 knockout mice were blocked by simultaneous Mlh1 
inactivation, suggesting that FAN1 acts to suppress the MLH1- 
dependent CAG expansions in HD patient tissues (14). Fan1 similarly 
suppresses somatic CGG repeat expansions in Fragile X mice (15). 
However, it remains to be demonstrated whether a direct physical 
interaction between FAN1 and MLH1 influences processing of dam-
aged DNA or expanded CAG repeats.
Here, we uncover the molecular details of human FAN1-MutL 
complexes and show that FAN1 interacts with MLH1 via two adja-
cent MLH1-binding sites, referred to as MLH1-interacting protein (MIP) 
box and MLH1-interacting motif (MIM). We further propose that 
the FAN1-MLH1 interaction is regulated during the cell cycle and 
inhibited in G2/M upon cyclin-dependent kinase 1/2 (CDK1/2)–
mediated phosphorylation of FAN1-S126 within the MIP box. We 
provide evidence that the same site can also be targeted by CDK5, 
an atypical and neuron-specific member of the CDK family. Func-
tionally, we demonstrate that the FAN1-MLH1 interaction promotes 
the assembly of both proteins into DNA damage foci in response to 
mitomycin C (MMC) treatment and is required for ICL and repeat 
slip-out processing but largely dispensable for MMR. Disruption 
of the FAN1-MLH1 interaction leads to hypersensitivity to DNA 
cross-linking agents and defective repair of slipped-CAG/CTG 
repeats. Both phenotypes are rescued when the MLH1 interaction–
defective FAN1 variant is additionally impaired in its endonuclease 
activity or dimerization. Together, our data provide a first mecha-
nistic rationale for the role of the FAN1-MLH1 complex in ICL re-
pair and CAT/CTG repeat stability.
RESULTS
FAN1-MLH1 interaction is regulated by phosphorylation 
of the MIP box in FAN1
To address these challenges, we first had to define the molecular 
details of the FAN1-MLH1 interaction. EXO1 and BLM bind to the 
C-terminal domain (CTD) of MLH1 via a tetrapeptide motif called 
the MIP box, with the consensus sequence Sx(Y/F)F (16–18). Sequence 
analysis revealed that FAN1 homologs contain a putative MIP box, 
126SPYF129 (Fig. 1A and fig. S1A). Isothermal titration calorimetry 
(ITC) measurements revealed that recombinant MLH1-CTD (fig. S1B) 
binds 8-mer peptides encompassing MIP motifs of human FAN1, 
EXO1, and BLM with similar affinities (Fig. 1B, fig. S1C, and table 
S3). FAN1 residues S126, Y128, and F129 (but not P127) are critical 
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for MLH1 interaction, as their substitution with alanines eliminated 
detectable binding to MLH1-CTD (Fig. 1B, fig. S1C, and table S3). 
Coimmunoprecipitation (co-IP) experiments in HEK293 cells 
transfected with FLAG-tagged FAN1 variants confirmed that 
S126A, Y128A, and Y128A/F129A (denoted as MIP*) impaired 
the interaction with endogenous full-length MLH1, while P127A 
had no effect (Fig. 1C). Residue E669 of MLH1 is known to be 
critical for its interaction with MIP box proteins (16, 19). FAN1 
and BLM were pulled down from HeLa nuclear extracts with 
MLH1-CTD wild-type (wt) but not with the E669A variant (fig. 
S2A), further confirming that FAN1 126SPYF129 represents a bona 
fide MIP box.
Phosphorylation at S126 in the 8-mer FAN1 MIP peptide abol-
ished interaction with MLH1-CTD (Fig. 1B, fig. S1B, and table S3). 
Analogously, a FAN1 phospho-mimetic mutant (S126E) failed to 
stably interact with MLH1 (fig. S2B). To confirm that FAN1 is S126- 
phosphorylated, we generated a phospho-specific antibody against 
FAN1-pS126 and found that it recognized FAN1  wt but not its 
S126A or P127A variants (Fig. 1D). The latter suggested that S126 
within the FAN1 MIP is likely to be phosphorylated by proline- 
directed kinases such as CDKs. Consistent with this idea, we found 
FAN1-pS126 levels to be substantially lower in cells expressing cat-
alytically inactive, dominant-negative mutants of CDK1 or CDK2 
(Fig. 1E and fig. S2C). Intriguingly, FAN1-S126 phosphorylation 
was also stimulated by CDK5 in the presence of its neuronal-specific 
activator p35 (fig. S2D).
To learn about the effect of key residues in FAN1, we used the 
“protein replacement” system to generate stable U2OS cell lines, in 
which endogenous FAN1 was knocked down and substituted by its 
inducibly expressed enhanced green fluorescent protein (eGFP)–
tagged variants (U2OSGFP-FAN1) (20). Treatment of U2OSGFP-FAN1 
cells with roscovitine, a pan-CDK inhibitor, or RO-3306, a selective 
CDK1 inhibitor, decreased FAN1-pS126 levels (fig. S2E), suggesting 
that FAN1-S126 phosphorylation is cell cycle–regulated. Synchro-
nization of HeLaGFP-FAN1 cells with nocodazole revealed that FAN1-
pS126 levels peak in G2/M are markedly reduced during G1 and remain 
low through S phase before rising again in G2 (fig. S2F). FAN1-pS126 
levels inversely correlated with the amounts of MLH1 interacting 
with FAN1 (Fig. 1F). Notably, MMC treatment reduced FAN1-S126 
phosphorylation (fig. S2G), likely as a consequence of DNA damage– 
induced cell cycle checkpoint activation. Together, these findings 
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Fig. 1. FAN1 contains a MIP box that is negatively regulated by CDK-mediated phosphorylation at S126. (A) Top: Protein domain architecture of human FAN1 indi-
cating the location of the MIP box. PIP, proliferating cell nuclear antigen–interacting peptide box; UBZ, ubiquitin-binding zinc finger; SAP, SAF-A/B, Acinus, and PIAS; TPR, 
tetratricopeptide repeat; NUC, nuclease. Bottom: Sequence alignment of the FAN1 orthologs with the MIP box of human EXO1 and BLM. (B) Dissociation constants (Kd) 
indicating the binding affinity of MLH1 CTD for the indicated peptides from FAN1, EXO1, and BLM as determined by ITC. NI, no interaction (weak and constant signal 
under the condition used). (C) Immunoblots of FLAG-M2 affinity resin immunoprecipitations (IPs) of extracts from HEK293 cells transfected either with empty vector (e.v.), 
FLAG-FAN1 wild type (wt), or the variant constructs. The Y128A/F129A mutation is denoted as MIP*. (D) Immunoblots of FLAG-M2 affinity resin IPs of extracts from HEK293 
cells transfected with the indicated FLAG-FAN1 constructs. (E) Immunoblots of FLAG-M2 affinity resin IPs of extracts from HEK293 cells cotransfected with FLAG-FAN1 and 
vectors expressing hemagglutinin (HA)–tagged dominant-negative (dn) forms of CDK1 or CDK2. (F) Immunoblots of green fluorescent protein (GFP)–Trap IPs of extracts 
from HeLaGFP-FAN1 cells synchronized in mitosis by thymidine-nocodazole block. Mitotic cells were replated in fresh medium for the indicated time periods. The relative 
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through the cell cycle by CDK-mediated phosphorylation of S126 in 
the FAN1 MIP box.
FAN1 contains a second conserved MLH1-binding site
Three human MLH1 partner proteins, MLH3, PMS2, and PMS1, 
share a homologous 36–amino acid domain implicated in MLH1 
interaction (21). Just downstream of the FAN1 MIP box, we noticed 
a highly conserved 12–amino acid sequence with extensive homol-
ogy to a part of that domain, which we therefore designated as MIM 
(Fig. 2A and fig. S3, A and B). ITC analyses revealed that MLH1-CTD 
binds 12-mer peptides encompassing MIMs of FAN1 and MLH3 
with similar affinities (Fig. 2B, fig. S3C, and table S3), suggesting 
that they may compete for the same binding site in MLH1. In con-
trast, the putative MIM peptide of PMS2 displayed lower binding 
affinity, while that of PMS1 was not stably interacting with MLH1-
CTD (Fig. 2B, fig. S3C, and table S3). We then mapped the critical 
residues within the FAN1 MIM for interaction with MLH1 through 
site-directed mutagenesis. Co-IP experiments with different FLAG-
FAN1 constructs revealed two highly conserved leucine residues, 
L155 and L159, to be primarily responsible for MLH1 interaction, 
with the corresponding double mutant L155A/L159A (denoted as 
MIM*) exhibiting a cumulative effect when compared to the single 
mutants (Fig. 2C and fig. S3D). ITC analysis of FAN1 and MLH3 
mutant MIM peptides further confirmed the critical role of the 
two leucine residues within their MIMs for MLH-CTD binding 
(fig. S3E).
To define the individual impact of MIP and MIM on MLH1 
binding, we subjected FAN1-derived 42-mer peptides containing 
both motifs (fig. S3A) to ITC analysis. Notably, having both MIP 
and MIM sites on a contiguous peptide resulted in ~40-fold in-
creased binding affinity to MLH1-CTD [dissociation constant 
(Kd) = 0.07 mM] compared to the MIP- or MIM-only peptides (Kd = 
2.8 and 3.2 mM, respectively) (Fig. 2B, fig. S3F, and table S3). This 
synergistic effect was not observed with 42-mer peptides carrying 
defective MIP* or MIM* variants (Fig. 2B, fig. S3F, and table S3). 
Independent contributions of each motif were corroborated for the 
full-length proteins by co-IP, showing that FLAG-FAN1 single MIP* 
or MIM* mutants exhibited residual interaction with MLH1, whereas 
the compound MIP*/MIM* mutant was fully deficient in binding 
to MLH1 (Fig. 2D). Last, GST-FAN1 pull-down assays with puri-
fied recombinant MutLa (MLH1-PMS2) or MutLg (MLH1-MLH3) 
confirmed the cooperativity between both motifs and demonstrated 
that FAN1 is unlikely to compete with PMS2 or MLH3 for MLH1 
binding (Fig. 2, E and F). We also observed specific binding of MutLa 
to GST-FAN1, using lysates from HEK293T cells transfected with 
MLH1- and PMS2-expressing vectors (fig. S3G). Together, our findings 
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FAN1 (12-mer, MIM) 152–163 3.2 ± 0.4
FAN1 (42-mer, MIP+MIM) 124–165 0.07 ± 0.02
FAN1 (42-mer-MIP*) 124–165 4.4 ± 0.7
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Fig. 2. An adjacent MLH1-interacting motif (MIM) in FAN1 synergizes with the MIP box to promote stable MLH1 binding. (A) Top: Protein domain architecture of 
human FAN1 indicating the location of the MIP box and MIM. Bottom: Sequence alignment of FAN1 orthologs with the putative MIM of human MLH3, PMS2, and PMS1. 
(B) ITC was used to determine the Kd indicating the binding affinity of MLH1-CTD for the indicated peptides. (C) Immunoblots of FLAG-M2 affinity resin IPs of extracts 
from HEK293 cells transfected either with e.v. or indicated FLAG-FAN1 expression constructs. The L155A/L159A mutation is denoted as MIM*. (D) Immunoblots of 
FLAG-M2 affinity resin IPs of extracts from HEK293 cells transfected either with e.v. or indicated FLAG-FAN1 expression constructs. (E and F) Recombinant MutLa (E) or 
MutLg (F) (200 nM) was subjected to pull-down reactions using the indicated recombinant GST-FAN1 (amino acids 118 to 177) variants. (C to F) The antibodies used 
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suggested that direct and specific docking of FAN1 to MLH1-CTD 
promotes the formation of stable complexes between FAN1 and 
MutLa or MutLg.
This prompted us to evaluate whether FAN1-MLH1 interaction 
functions in MMR, although currently available data do not indi-
cate a prominent role for FAN1 in this repair pathway (4). Acquired 
resistance to DNA alkylating agents generating O6-methylguanine–
containing mismatches, such as the chemotherapeutic temozolomide 
(TMZ), is a common feature of MMR-deficient tumor cells (22–24). 
Consistent with this, depletion of MLH1 from U2OS cells results in 
TMZ resistance (fig. S4, A to C). In contrast, cells depleted of FAN1, 
or cell lines inducibly expressing FAN1 mutants either defective in 
nuclease activity (D960A, nd*) or MLH1 binding (MIP*/MIM*), 
were efficiently killed by TMZ (fig. S4, A to C), indicating that the 
FAN1-MLH1 interaction is unlikely to act in canonical MMR.
FAN1-MLH1 interaction confers resistance to  
cross-link damage
To confirm the existence of FAN1-MLH1 complexes in cells, we 
performed in situ proximity ligation assays (PLA). Nuclear PLA signals 
were readily detected in U2OS cells inducibly expressing GFP-FAN1 
wt but not the MIP*/MIM* variant and significantly increased in 
number upon MMC treatment, indicating that the FAN1-MLH1 
interaction might operate in ICL repair (Fig. 3A). To corroborate 
this finding, we generated a mouse monoclonal antibody against 
the nuclease domain of human FAN1 (amino acids 871 to 1017), 
specifically detecting endogenous FAN1 expression in U2OS nucle-
ar extracts and HeLa whole-cell lysates by Western blotting (fig. S5, 
A and B). Using this new tool, we could confirm the MMC-dependent 
increase in the number of nuclear FAN1-MLH1 PLA foci in HeLa 
cells (fig. S5C).
Increased MMC hypersensitivity was evident in cells expressing 
the MLH1 interaction–defective FAN1 MIP*/MIM* variant compared 
to cells expressing FAN1 wt (Fig. 3, B to E, and fig. S5, D and E). 
Simultaneous loss of MLH1 binding and DNA nuclease activity 
(=MIP*/MIM*/nd*) rescued clonogenic survival after MMC treat-
ment to near wt levels (Fig. 3, C and E, and fig. S5D). We observed 
nearly identical chemosensitivity profiles upon treatment of these 
cells with the ICL-inducing agent cisplatin (fig. S5, F and G). The 
FAN1 D960A (nd*) mutant is completely deficient in both endo- 
and exonuclease activities (25). In contrast, the FAN1 triple mutant 
(K525E/R526/K528E, here referred to as dim*; Fig. 3B) incapacitates 
both FAN1 head-to-tail dimerization and endonucleolytic activity 
while retaining exonucleolytic activity (25). Notably, expression of 
the compound MIP*/MIM*/dim* FAN1 variant also fully restored 
MMC resistance (Fig. 3, D and E, and fig. S5E).
Loss of FAN1-MLH1 interaction results in persistent 
ssDNA signaling
Quantitative image-based cytometry (QIBC) analysis established that 
homodimerization is required for FAN1 foci formation in response 
to MMC treatment, whereas MLH1 binding is largely dispensable 
(Fig. 4A and fig. S6A). Conversely, MLH1 localization to ICL dam-
age was significantly impaired in both FAN1 dim* and MIP*/MIM* 
variants, indicating that accumulation of MLH1 at ICLs relies on its 
physical interaction with FAN1 (fig. S6B). Moreover, we found that 
cells expressing the MIP*/MIM* variant displayed a prolonged 
G2/M arrest after MMC treatment, which was not observed in cells 
expressing the MIP*/MIM*/dim* (Fig.  4B and fig. S6C). Single- 
stranded DNA (ssDNA) accumulated in MMC-treated MIP*/MIM*- 
expressing G2/M cells compared to FAN1 wt cells, as detected by 
native 5-bromo-2′-deoxyuridine (BrdU) staining (fig. S6D). Accu-
mulation of ssDNA was not observed in MIP*/MIM*/dim* cells 
(fig. S6D). Replication protein A (RPA), a heterotrimeric complex 
consisting of RPA1, RPA2, and RPA3 subunits, is the major ssDNA 
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Fig. 3. FAN1-MLH1 interaction promotes resistance to cross-link damage. (A) PLA was used to evaluate FAN1-MLH1 association in U2OSGFP-FAN1 wt and U2OSGFP-FAN1 
MIP*/MIM* cells mock-treated or treated with MMC (150 ng/ml) for 24 hours. Representative images are shown. Scale bars, 10 mm. Scatterplot displays quantification of the 
PLA signals per nucleus from at least 100 cells. Data display the means ± SD from three independent experiments. Statistical significance was calculated by unpaired t test. 
**P < 0.01; ns, not significant. (B) Schematic representation of human FAN1, highlighting positions of mutations used, including MIP*, MIM*, dimerization-defective 
(dim*), and nuclease-defective (nd*) FAN1 variants. (C and D) Immunoblots of GFP-Trap IPs of extracts from indicated U2OSGFP-FAN1 cells. The antibodies used are shown 
on the left. (E) Clonogenic survival assay of the indicated U2OSGFP-FAN1 cells exposed to increasing doses of MMC. Viability of untreated cells was defined as 100%. Data 
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DNA replication and repair (26). Consistently, we found increased 
RPA1 and RPA2 loading on MMC-damaged chromatin in cells ex-
pressing the MIP*/MIM* variant but not in cells expressing MIP*/
MIM*/nd* (nuclease-dead) or MIP*/MIM*/dim* (defective in endo- 
but not exonuclease) forms of FAN1 (Fig. 4C and fig. S6, E and F). 
Last, both CHK1 and RPA2 phosphorylation were elevated in MIP*/
MIM* cells upon 24-hour treatment with a high dose of MMC 
(Fig.  4D), indicative of activation of the DNA damage response. 
This effect was somewhat diminished for the MIP*/MIM*/nd* or 
MIP*/MIM*/dim* relative to the MIP*/MIM* (Fig. 4D). Together, 
these findings are consistent with the idea that correct MLH1 bind-
ing is critical to prevent cytotoxic endonucleolytic DNA cleavage by 
MLH1-free FAN1 in response to ICL damage.
FAN1-MLH1 interaction promotes DNA repair 
of CAG slip-outs
Several studies have implicated FAN1 in repeat diseases (8–10, 15). 
Repeat expansions occur because of aberrant or escaped repair of 
unusual slipped-DNA structures that form upon out-of-register 
annealing of complementary repeat strands during DNA repair, 
replication or transcription (27, 28). Slipped-DNAs occur at the ex-
panded CAG/CTG repeat disease locus in myotonic dystrophy type 
1 patient tissues, where their levels directly correlated with the levels 
of somatic repeat expansions, providing support for the involve-
ment of slipped-DNAs in expansions (29). We therefore set out to 
investigate the involvement of the FAN1-MLH1 complex in the 
processing of slipped-strand DNAs formed by CAG/CTG repeats, 
using an established in vitro slipped-DNA repair assay (30–32). 
Modulation of CAG instability with a ligand that binds to slipped-
DNAs in brains of HD mice, where the ligand also blocked in vitro 
CAG slip-out repair by cell extracts, supports this assay as an impres-
sion of the in vivo maintenance of CAG repeats (30). We previously 
demonstrated the requirement of a DNA nick for strand-specific 
slip-out repair, as in base-base MMR, the nick determines the 
strand that will be repaired and the continuous strand serves as the 
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Fig. 4. FAN1-MLH1 interaction prevents extensive ssDNA formation following cross-link damage. (A) QIBC analysis of GFP-FAN1 foci in U2OSGFP-FAN1 cells 
mock-treated, treated with MMC (20 ng/ml) for 24 hours, or MMC-treated and then released for 72 hours. Color-coded scatterplots indicate the number of GFP-FAN1 foci 
per nucleus. ut, untreated. (B) Same cells as in (A) were pulse-labeled with ethynyl deoxyuridine (EdU) during the last 30 min before harvesting and subjected to the Click-
IT reaction. Cell cycle distribution was evaluated by QIBC using the 4′,6-diamidino-2-phenylindole (DAPI) and EdU signals (fig. S5C). (C) QIBC of RPA2 foci in U2OSGFP-FAN1 
cells mock-treated, treated with MMC (20 ng/ml) for 24 hours, or MMC-treated and then released for 72 hours. Color-coded scatterplots indicate the number of RPA2 foci 
per nucleus. A.U., arbitrary units. (D) Same cells as in (C) were treated with MMC (300 ng/ml) for 24 hours, and lysates were analyzed by immunoblotting using the indicat-
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of base-base mismatches and heteroduplexes with limited strand 
bias. The cell extract preparations used for slip-out repair are com-
petent in a broad range of DNA repair processes, including MMR, 
and are capable of inducing replication-mediated CAG/CTG repeat 
expansions and contractions (33). We and others revealed that 
MLH1 is required for the repair of short slip-outs of a single excess 
repeat (34, 35). Thus, before interrogating the role of the FAN1-MLH1 
interaction in slip-out repair, we first established the sensitivity of 
long slip-out (excess of 20 repeats) repair to MLH1 levels. The 
repair-proficient human cell line TK6 and its MLH1-null CRIS-
PR-Cas9–produced derivative have been described (36). Using TK6 
and TK6-MLH1−/− cell extracts, we reveal that MLH1 is involved in 
slip-out repair, and repair efficiency depended specifically on the 
titrated levels of MLH1 (fig. S7A). A parallel experiment using extracts 
of the MLH1-null HCT116 and its corrected derivative HCT116 + 
chromosome 3 (37) revealed identical results (fig. S7B). Thus, the 
repair of both short and long slip-outs is sensitive to MLH1.
The involvement of the FAN1-MLH1 interaction was next as-
sessed. Specifically, extracts from U2OS clones inducibly expressing 
GFP-FAN1 variants were tested for their capacity to repair slipped-
DNA substrates that model repeat contraction or expansion inter-
mediates, containing a nick on the opposite or on the same strand 
of the slip-out, respectively (Fig. 5A). We established that the MLH1 
interaction–defective FAN1 MIP*/MIM* variant was significantly 
less efficient in mediating the repair of a substrate with 20 excess 
CAG repeats than the FAN1 wt protein (fig. S8A). Thus, efficient 
repair of slipped-CAG/CTG repeats requires the FAN1-MLH1 in-
teraction. Next, we found that slip-out repair was restored when 
MLH1 interaction–defective FAN1 protein was also made defective 
in either its DNA nuclease activity (MIP*/MIM*/nd*) or in dimer 
formation (MIP*/MIM*/dim*), a scenario which is analogous to the 
MMC-induced cellular phenotypes (Fig. 5B and Fig. 3E). Identical 
results were observed with all long slip-out substrates tested, re-
gardless of the slip-out repeat motif (CAG or CTG) or location of 
the nick (fig. S8, B to D). Conversely, the FAN1-MLH1 interaction 
was dispensable for the processing of short, isolated single repeat 
slip-outs (fig. S9, A and B). To further validate the importance of 
the FAN1-MLH1 interaction in the repair of repeat slip-outs, we 
synthesized a FAN1 peptide containing both MLH1-binding motifs 
that efficiently inhibited complex formation between endogenous 
FAN1 and MLH1 in HeLa extracts (Fig. 5C). Supplementing the 
extracts with the FAN1 wt peptide caused a concentration-dependent 
decrease in CAG slip-out repair, which was not observed with the 
compound MIP*/MIM* mutant peptide (Fig. 5D). The peptide se-
lectively inhibited the FAN1-MLH1 interaction, as it did not cause 
a further reduction in slip-out repair when added to extracts de-
rived from MIP*/MIM* mutant U2OS cells (Fig. 5E).
DISCUSSION
Here, we revealed the molecular basis of the interaction between FAN1 
and MLH1, its negative regulation by CDK-mediated phosphorylation 
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Fig. 5. FAN1-MLH1 interaction promotes repair of CAG/CTG DNA slip-outs. (A) Scheme of the slipped (CTG)30/(CAG)50 substrate. (B) The (CAG)20 slip-out substrate 
was incubated with extracts from U2OSGFP-FAN1 cells expressing indicated FAN1 variants. Repair efficiency was quantified by densitometric analysis of Southern blots. 
Values represent the mean of three independent experiments. Error bars represent ±SD. Statistical significance was calculated by ordinary one-way analysis of variance 
(ANOVA) test followed by Tukey’s multiple comparisons. **P < 0.005, ***P < 0.0005, ****P < 0.00005. (C) HeLa nuclear extract was incubated with FAN1-derived 60-mer 
peptides (amino acids 118 to 177) containing wt or mutant MIP-MIM, immunoprecipitated using anti-FAN1 antibody, and immunoblotted with the indicated antibodies. 
(D) Extracts from HeLa cells were supplemented with increasing concentrations of FAN1 peptides and incubated with the (CAG)20 slip-out substrate. Repair efficiency was 
calculated as described in (B). (E) Extracts of U2OSGFP-FAN1 wt and U2OSGFP-FAN1 MIP*/MIM* cells were supplemented with indicated FAN1 peptides and incubated with the 
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of FAN1-S126, and its functional relevance for processing ICLs and 
slipped-DNA intermediates of repeat expansion mutations (as 
detailed in Fig. 6). Our data suggest that disrupting FAN1-MLH1 
association, either by MIP-MIM mutations or by a MIP-MIM mi-
metic peptide, can lead to less efficient ICL processing leading to 
enhanced cytotoxicity and diminished repair of slipped-DNAs. 
When FAN1 is unable to bind MLH1, additional loss of FAN1 
endo- but not exonuclease activity can restore both deleterious 
traits associated with disruption of the FAN1-MLH1 interaction. 
Given that the FAN1-MLH1 interaction protects cells from ICL- 
induced cell death, its modulation might be harnessed to enhance 
MMC chemosensitivity for cytoreductive surgical debulking in cas-
es of persistent MMC chemoresistance (38). Likewise, the rescue of 
reduced slip-out repair in extracts expressing the MLH1 interaction– 
defective FAN1 occurs when FAN1 is also endonuclease-defective 
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Fig. 6. FAN1-MLH1 interaction affects the repair of ICLs and slipped-DNA repeats. Summary of the FAN1-MLH1 complex interaction and a plausible model for its 
involvement in ICL and slip-out repair. (A) Scheme of the FAN1-MLH1 interaction in different states of wt or mutated FAN1. Protein orientation is unknown and arbitrarily 
presented for ease. (B) Left: FAN1 is subjected to CDK-mediated phosphorylation at S126 located within the MIP box. Right: Regulation of FAN1-MLH1 interaction through 
the cell cycle and in response to ICL damage. (C) Top: The FAN1-MLH1 complex localizes to ICL damaged chromatin to preserve genome stability and ensure cell viability. 
In cells, devoid of the FAN1-MLH1 interaction aberrant ICL repair and cell death ensues. Inactivation of FAN1’s endo- and exonuclease activities by mutating D960A or 
inhibition of FAN1 dimerization, affecting FAN1’s endo- but not exonucleolytic activity, would alleviate the toxicity of the FAN1 MIP/MIM-mutated variant and promote 
cell proliferation and survival. Bottom: Inhibition of the FAN1-MLH1 interaction (MIP*/MIM*) blocks repair of slipped-DNAs. Repair defects were rescued when the 
MLH1-interacting–defective FAN1 was also defective either in both its endonuclease activities or in dimer formation (endo- but not exonuclease defective). Therefore, the 
regulatory aspects of the FAN1 binding to MLH1 aligns the pathway of ICL repair with that of slipped-DNA processing. Mutations: MIP*, Y128A/F129A; MIM*, L155A/
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of the slip-out substrates by MLH1-free FAN1 diminishes slip-out 
repair. Moreover, peptide-mediated suppression of MLH1 binding 
to FAN1 also inhibits slip-out repair in vitro. Thus, modulation of 
the FAN1-MLH1 interaction might represent a novel opportunity 
to alter the metabolism of disease-associated repeats.
The MutLa (MLH1-PMS2) endonuclease, activated by MutSb 
(MSH2-MSH3), PCNA, and RFC, can weakly incise both strands of 
short CAG or CTG slip-out containing DNAs (1 to 4 excess repeat 
units), without displaying a strand or polarity bias (35). In contrast, 
the MutLg (MLH1-MLH3) endonuclease, activated by MutSb, prefer-
entially incises the strand opposite of CAG or CTG slip-outs, often 
cleaving upstream or downstream of the slip-out DNA (12). FAN1 
and the MMR genes MSH3, MLH1, MLH3, and PMS2 were identi-
fied as genetic modifiers of the age-of-onset of HD families and at 
least six other CAG repeat expansion disorders (39). Specifically, 
noncoding and coding variants of these DNA repair genes are asso-
ciated with an earlier or later age of disease onset (40). MMR pro-
teins are required for somatic CAG and CGG expansions in tissues 
of HD, Myotonic dystrophy type 1 (DM1), and Fragile X syndrome 
(FXS) transgenic mice, as their deficiency leads to stabilization of 
CAG/CTG repeat tracts (41). Specifically, in the absence of Mlh1 
and Mlh3, the spontaneous ongoing ultrafrequent somatic CAG ex-
pansions arising in wt mice were completely stabilized, while in 
the absence of Pms2, somatic expansions were partially stabilized 
and very rare large contractions (~1.6 to 14 contractions per 
1000 cells; >20 U per event) were increased by 1.5- to 3.5-fold (42). 
This contrasts with the increased hyperexpansions of repeats in 
tissues that arise in the absence of Fan1 (14). Curiously, HD mice 
deficient for both Mlh1 and Fan1 showed no somatic CAG expan-
sions, indicating that MLH1 is critical for driving repeat instability 
in FAN1-deficient mice (14). Interpretations of this are that MLH1 
is strictly required (i) for FAN1’s apparent ability to suppress hyper-
expansion or (ii) to drive the hyperexpansions, which are otherwise 
suppressed by FAN1. It is nonetheless perplexing that FAN1 and 
MLH1, which form a complex, have completely opposing effects 
on the spontaneous ongoing CAG expansions in tissues of HD 
mice, which reflect somatic expansions in patients. Mlh1 is ab-
solutely required to drive CAG expansions, as Mlh1 deficiency 
abolishes expansions (11). In contrast, Fan1 deficiency leads to 
enhanced somatic CAG expansion rates in cultured patient cells and 
HD mice, suggesting that the role of FAN1 in HD patients is to 
attenuate the levels of CAG expansion (10, 13, 14). It is tempting to 
speculate that the rate of repeat expansion and thus of disease onset 
might be controlled by the FAN1-MLH1 interaction status. Usdin 
and colleagues (43) revealed that Exo1, which interacts with Mlh1 
through its MIP box, could suppress against Mlh1-dependent 
CGG expansions in Fragile X mice. Further studies are clearly 
needed to establish the determinants of how expanded repeats are 
processed by MutL complexes interacting mutually exclusive with 
FAN1 or EXO1.
Squitieri and colleagues (44) showed that MMC treatment of 
HD patient cells significantly diminished the rate of ongoing CAG 
expansions of the mutant HTT but did not affect the nonexpanded 
gene. This suggests that DNA lesions, whose repair involves the 
FAN1-MLH1 complex and its regulation by posttranslational mod-
ification, can indeed have an impact on CAG instability. Overall, 
our findings presented herein begin to dissect the critical interac-
tions and reveal commonalities of the FAN1-MLH1 complex in ICL 
processing and repeat stability/instability.
MATERIALS AND METHODS
Cell culture
U2OS, HEK293, HEK293T (Invitrogen, Life Technologies), and HeLa 
Kyoto FAN1 N-FLAP (The Hyman Lab, MPI-CBG) cells were grown 
in Dulbecco’s modified Eagle’s medium (DMEM) supplemented 
with 10% fetal calf serum (FCS), penicillin (100 U/ml), and strepto-
mycin (100 mg/ml). HCT116 cells were grown in McCoy’s 5A medium 
supplemented with 10% FCS, penicillin (100 U/ml), and streptomy-
cin (100 mg/ml). TK6 cells were cultivated in RPMI 1640 medium 
supplemented with 10% heat-inactivated horse serum (Gibco, Life 
Technologies), sodium pyruvate (200 mg/ml), penicillin (100 U/ml), 
and streptomycin (100 mg/ml). U2OS Flp-In T-REx and HeLa Flp-
In T-REx (Invitrogen, Life Technologies) cells were maintained in 
medium supplemented with blasticidin (10 mg/ml) and hygromycin 
B (250 mg/ml). The Flp-In T-REx system (Thermo Fisher Scientific) 
was used to generate cell lines stably expressing different short hair-
pin RNA (shRNA)–resistant forms of GFP-FAN1 constructs under 
the control of a doxycycline (Dox)–inducible promoter (20). To learn 
about the effect of key residues in FAN1, as previously, we used this 
protein replacement system to generate stable U2OS cell lines, in 
which the endogenous FAN1 was knocked down by coexpression of 
an anti-FAN1 shRNA and substituted by its eGFP-tagged variants. 
This method makes use of a stably integrated vector containing two 
Dox-inducible cassettes: one expressing shRNA targeting mRNA that 
encodes an endogenous protein of choice and the second express-
ing cDNA encoding the desired protein variants. Dox treatment of 
these stable cell lines leads to degradation of the mRNA encoding 
the endogenous FAN1 protein and to expression of the desired vari-
ants. Briefly, expression vectors pAIO-TO/eGFP-FAN1 and the Flp 
recombinase expression plasmid, pOG44, were mixed in a 1:9 ratio 
and transfected into U2OS or HeLa Flp-In T-REx cells using Lipo-
fectamine 3000 (Thermo Fisher Scientific). Forty-eight hours later, 
cells were plated at different dilutions and, 72 hours after transfection, 
the medium was supplemented with hygromycin B (250 mg/ml) and 
blasticidin S (12.5 mg/ml). The medium was replaced every 2 to 3 days, 
and the cells were maintained in selection medium for approximately 
14 days. Resistant colonies were picked and single-cell clones ana-
lyzed for GFP expression by flow cytometry and immunoblotting. 
For G2/M synchronization, HeLa
GFP-FAN1 Flp-In T-REx cells were 
cultured in the presence of 2 mM thymidine for 24 hours, released for 
3 hours, and then incubated with nocodazole (100 ng/ml) for 18 hours, 
washed three times with 1× phosphate-buffered saline (PBS) and 
cultured for the indicated times in DMEM growth medium.
Antibodies and plasmids
A complete list of all primary antibodies and DNA plasmids used 
throughout this study can be found in tables S1 and S2, respectively. 
Secondary horseradish peroxidase (HRP)–conjugated anti-mouse 
and anti-rabbit antibodies were from GE Healthcare, and the HRP- 
conjugated anti-goat antibody was from Santa Cruz Biotechnology. 
Alexa Fluor 488, 594, and 647–conjugated secondary antibodies 
were purchased from Thermo Fisher Scientific. The phospho- 
specific antibody against FAN1-pS126 was produced by Cre-
ative Biolabs (NY, USA) by immunizing rabbits with a synthetic 
keyhole limpet hemocyanin–conjugated FAN1 phospho-peptide 
(119-REVKQKIpSPYFKSN-132) of human FAN1. The monoclonal 
antibody against FAN1 was produced by GenScript (NJ, USA) by 
immunizing mice with recombinant His-tagged FAN1 (amino acids 
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Chemicals
BrdU, 4′,6-diamidino-2-phenylindole (DAPI), MMC, thymidine, 
nocodazole, cisplatin, O6-benzylguanine (O6-BG), and TMZ were 
purchased from Sigma-Aldrich. R-roscovitine and RO-3306 
were purchased from Calbiochem. Dox was purchased from TaKaRa 
Clontech.
Isothermal titration calorimetry
Human MLH1 CTD (amino acids 486 to 756) was purified for ITC 
analyses as described previously (fig. S1B) (16, 17). The synthetic 
peptides used in this study were purchased from GeneCust (Boynes, 
France) at 95% purity. The binding between MLH1(CTD) and the 
different peptides was measured by using a VP-ITC (Cytiva). Before 
the measurements, all the solutions were degassed under vacuum. 
The reaction cell was loaded with 15 mM MLH1 protein, and the 
syringe contained 150 mM peptide solutions. Thirty injections of 
10-ml volume were made at 210-s intervals. Control experiments 
were performed at the same concentration of peptides with buffer 
in the cell. Thermodynamic parameters DH° (enthalpy change), n 
(stoichiometry), and Ka (association constant) were obtained by 
nonlinear least-squares fitting of the experimental data by using the 
single set of independent binding sites model of the Origin software 
provided with the instrument. The free energy of binding (DG°) and 
entropy (DS°) were obtained by using the classical thermodynamic 
formulae: DG° = −RT × ln Ka and DG° = DH°–TDS°, where R is the 
gas constant and T is the absolute temperature in kelvin. The titra-
tions were carried out at 30°C in 50 mM Na2HPO4 (pH 8.0), 150 mM 
NaCl, and 10 mM b-mercaptoethanol. See table S3 for the summary 
of all ITC data.
His-MLH1 pull-down assays
His6-GST-MLH1-CTD constructs were expressed in E. coli strain 
BL21. Cultures were grown at 37°C with shaking at 250 rpm. Pro-
tein expression was induced at OD600 (optical density at 600 nm) 
0.6 by the addition of 0.5 mM isopropyl-b-D-thiogalactopyranoside 
at 18°C for 20 hours. The cells were lysed in lysis buffer [1× PBS, 1% 
Triton X-100, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM 
benzamidine, and 1× complete protease inhibitor cocktail (Roche)] 
and sonicated for 5 min. The mixture was rotated at 4°C for 1 hour. 
The soluble fraction was retrieved by centrifugation at 13,000 rpm 
at 4°C for 30 min and incubated with nickel–nitrilotriacetic acid 
beads in pull-down buffer for 2 hours at 4°C. HeLa nuclear extract 
(CilBiotech) was incubated with MLH1-bound beads for 2 hours 
at 4°C. The beads were washed three times with NTEN300 [0.5% 
NP-40, 20 mM tris-HCl (pH 7.4), 0.1 mM EDTA, and 300 mM 
NaCl] and once with TEN100 [20 mM tris-HCl (pH 7.4), 0.1 mM 
EDTA, and 100 mM NaCl]. The recovered complexes were boiled in 
SDS sample buffer and analyzed by SDS–polyacrylamide gel elec-
trophoresis (PAGE) followed by immunoblotting.
Coimmunoprecipitation
Following procedures previously described in (45), cells were lysed 
in NP-40 buffer [50 mM tris-HCl (pH 7.5), 120 mM NaCl, 1 mM 
EDTA, 6 mM EGTA, 15 mM sodium pyrophosphate, and 1% NP-40, 
supplemented with phosphatase inhibitors (20 mM NaF and 1 mM 
Na3VO4) and protease inhibitors (1 mM benzamidine and 0.1 mM 
PMSF)], incubated with Benzonase (Merck) for at least 30 min at 
4°C, and clarified by centrifugation. A total of 1 to 3 mg of lysates 
was incubated with anti-FLAG M2 (Sigma-Aldrich) or GFP-Trap 
affinity resin (ChromoTek) for 2 hours or overnight at 4°C. The 
beads were then washed three times with NP-40 buffer and once 
with TEN100 [50 mM tris-HCl (pH 7.5), 140 mM NaCl, and 5 mM 
EDTA]. Retrieved protein complexes were boiled in SDS sample 
buffer and analyzed by SDS-PAGE followed by immunoblotting.
FAN1 60-mer peptides
Custom-designed FAN1 60-mer peptides (amino acids 118 to 177), wt, 
and MIP*/MIM* (Y128A/F129A/L155A/L159A) were purchased 
from GenScript and synthesized according to standard practice 
(N-terminal acetylation and C-terminal amidation). Lyophilized 
peptides with a purity >85% were dissolved in water at 5 mg/ml.
FAN1 immunoprecipitation
One milligram of HeLa nuclear extract was incubated with or without 
15 mM FAN1 60-mer peptides in 0.5 ml of NP-40 buffer for 2 hours 
at 4°C with rotation. One microgram of anti-FAN1 rabbit polyclonal 
antibody was added to the samples and incubated overnight at 4°C 
with rotation. Protein A Sepharose beads (CL4B, Sigma-Aldrich) were 
equilibrated in NP-40 buffer, and 25 ml of bead slurry was then added 
to each sample and incubated for 2 hours at 4°C with rotation. The 
beads were then washed three times with NP-40 buffer and once 
with 1× TEN100 buffer, boiled in SDS sample buffer, and analyzed 
by SDS-PAGE followed by immunoblotting.
siRNA transfections
Small interfering RNA (siRNA) oligos were transfected at a final 
concentration of 20 nM using Lipofectamine RNAiMAX (Thermo 
Fisher Scientific). FAN1 (5′-GUAAGGCUCUUUCAACGUA-3′) 
and MLH1 (5′-GUGUUCUUCUUUCUCUGUA-3′) siRNAs were 
purchased from Microsynth. CNTL siRNA was purchased from 
Ambion (catalog no. 4390846).
Colony formation assays
For TMZ treatment, U2OS cells were transfected with siCNTL, 
siFAN1, or siMLH1 for 24 hours. The cells were then plated in 
six-well plates previously coated with poly-L-lysine (0.01%, Sigma- 
Aldrich). U2OSGFP-FAN1 cells were seeded in the presence of Dox 
(100 ng/ml) in six-well plates. Twenty-four hours after seeding, the 
cells were treated with 10 mM O6-BG for 2 hours. The medium was 
then replaced with serum-free medium supplemented or not with 
TMZ for 3 hours, and the cells were then washed twice with 2 ml of 
1× PBS before adding add fresh growth medium. For MMC and 
cisplatin treatment, U2OSGFP-FAN1 cells were seeded in the presence of 
Dox (100 ng/ml) in six-well plates. Twenty-four  hours after the 
seeding, the cells were treated with MMC or cisplatin for 24 hours. 
For MMC colony formation assays, plates were then washed twice 
with 2 ml of 1× PBS before adding fresh growth medium. For 
cisplatin colony formation assays, medium was left on the plates 
after 24 hours of treatment and topped up with fresh growth medium. 
In all colony formation assays, the cells were cultured for 13 days at 
37°C before fixation with crystal violet solution [0.5% crystal violet and 
20% ethanol (w/v)]. For analysis, plates were scanned and analyzed 
with the ImageJ Plugin ColonyArea using the parameter “intensity 
percent” (46).
Immunoblotting
If not stated otherwise, cells were lysed in NP-40 buffer supplemented 
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protease inhibitors (1 mM benzamidine and 0.1 mM PMSF), incu-
bated with Benzonase (Merck) for at least 30 min at 4°C, and clari-
fied by centrifugation. Nuclear and cytoplasmic fractions of U2OS 
cells were generated according to the nuclear extraction protocol of 
Thermo Fisher Scientific. Proteins were resolved by SDS-PAGE and 
transferred to nitrocellulose membranes. Immunoblots were per-
formed with the indicated antibodies, and proteins were visualized 
using the Advansta WesternBright ECL reagent and the Fusion Solo 
S imaging system.
In situ PLA
U2OSGFP-FAN1 cells were seeded in the presence of Dox (100 ng/ml). 
Twenty-four hours after seeding, U2OSGFP-FAN1 or HeLa cells were 
grown in the absence or presence of MMC (150 ng/ml) for 24 hours. 
Following procedures previously described in (47), cells were pre-
extracted for 5 min on ice and fixed in 4% formaldehyde in 1× PBS 
(w/v) for 15 min on ice. In situ PLA was performed using Duolink 
PLA technology (Sigma-Aldrich) according to the manufacturer’s 
instructions. Briefly, coverslips were blocked for 30 min at 37°C and 
incubated with the respective primary antibodies for 1 hour at room 
temperature (RT). Coverslips were washed twice in 1× PBS for 
5  min. Then, anti-Mouse PLUS and anti-Rabbit MINUS PLA 
probes (Sigma-Aldrich) were coupled to the primary antibodies for 
1 hour at 37°C. After three wash steps in wash buffer A (10 mM tris, 
150 mM NaCl, and 0.05% Tween 20) for 5 min, the PLA probes were 
ligated for 30 min at 37°C. The coverslips were then washed three 
times for 5 min in wash buffer A. Amplification using the “Duolink 
In Situ Detection Reagents Red” (Sigma-Aldrich) was performed at 
37°C for 100 min. After amplification, the coverslips were washed 
twice in wash buffer B (200 mM tris and 100 mM NaCl) for 10 min 
and once in 0.01× wash buffer B for 1 min. Last, the coverslips were 
mounted using Vectashield Mounting Media (Vector Laboratories) 
containing DAPI dihydrochloride, sealed and imaged on a Leica 
DMI 6000 fluorescence microscope at ×63 magnification.
Quantitative image–based cytometry
Following procedures previously described in (48), automated mul-
tichannel wide-field microscopy for QIBC was performed on an 
Olympus ScanR Screening system equipped with an inverted mo-
torized Olympus IX83 microscope, a motorized stage, infrared- 
laser hardware autofocus and a Hamamatsu ORCA-FLASH 4.0 V2 
cooled scientific complementary metal-oxide semiconductor cam-
era (2048 × 2048 pixels; pixel size, 6.45 mm by 6.45 mm; 12-bit dy-
namics). Images were analyzed with the Olympus ScanR Image 
Analysis Software version 3.0.1, a dynamic background correction 
was applied, nuclei segmentation was performed using an integrat-
ed intensity–based object detection module using the DAPI signal, 
and foci segmentation was performed using an integrated spot de-
tection module. All downstream analyses were focused on properly 
detected nuclei containing a 2C-4C DNA content as measured by 
total and mean DAPI intensities. Fluorescence intensities were 
quantified and are depicted as arbitrary units. Color-coded scatter-
plots of asynchronous cell populations were generated with Spotfire 
data visualization software version 7.0.1 (TIBCO). Within one ex-
periment, similar cell numbers were compared for the different 
conditions. For visualizing discrete data in scatterplots, mild jitter-
ing (random displacement of data points along the discrete data 
axes) was applied to demerge overlapping data points. Represent-
ative scatterplots are shown.
Immunofluorescence microscopy
U2OSGFP-FAN1 cells were grown on 13-mm coverslips. The cells 
were treated with MMC (20 ng/ml) for 24 hours, followed by release 
into fresh DMEM growth media for 72 hours where indicated. 
Ethynyl deoxyuridine (EdU) labeling was performed for the last 
30 min as previously described. The cells were incubated with 0.5% 
Triton X-100 in PBS for 2 min, washed one time in 1× PBS before 
fixation in 4% formaldehyde in 1× PBS for 15  min. The primary 
antibodies and secondary antibodies were diluted in filtered DMEM 
containing 10% FCS and 0.02% sodium azide. Antibody incubation 
was performed for 1 to 2 hours at RT. Following antibody incuba-
tion, the cells were washed once with 1× PBS and incubated for 
10 min with 1× PBS containing DAPI (0.5 mg/ml). After three wash-
ing steps with 1× PBS, the coverslips were briefly washed with dis-
tilled water and mounted on glass slides with 6 ml of Mowiol-based 
mounting media [Mowiol 4.88 (Calbiochem) in glycerol/tris).
Native BrdU assay
U2OSGFP-FAN1 cells were seeded in the presence of Dox (100 ng/ml) 
and BrdU (25 mM). Twenty-four hours after seeding, the cells were 
treated or not with MMC (20 ng/ml) for 24 hours. Plates were then 
washed twice with 1× PBS before adding fresh growth medium con-
taining Dox (100 ng/ml) and BrdU (25 mM). Forty-eight hours later, 
cells were harvested by trypsinization and preextracted in 0.2% Tri-
ton X-100/1× PBS for 10 min on ice. After fixation in 4% formalde-
hyde/1× PBS, cells were washed three times with 1% bovine serum 
albumin/PBS. Cells were incubated in 1× Perm/Wash buffer (BD 
Biosciences) containing the primary antibody against BrdU for 1 hour 
at RT, followed by a wash step with 1× Perm/Wash buffer. For 
secondary antibody staining, cells were incubated in 1× Perm/Wash 
buffer (BD Biosciences) containing Alexa Flour 647–conjugated 
secondary antibody for 1 hour at RT, followed by a wash step with 
1× Perm/Wash buffer. Cells were then counterstained with DAPI 
(1 mg/ml)/ribonuclease (0.1 mg/ml), and fluorescence was measured 
on an Attune NxT Flow Cytometer (Thermo Fisher Scientific) and 
analyzed with FlowJo X (Tree Star).
Slipped-DNA repair assay
A set of previously characterized human DM1 mutagenic interme-
diates containing pure (CTG)x•(CAG)y repeats where x = 30 or 50 
and y = 50 or 30 have been used to perform slipped-strand repair 
reactions. Circular slipped hybrid DNAs were prepared by hybrid-
izing linearized double-stranded DNAs to circular ssDNAs con-
taining different numbers of repeats. Circular slipped hybrids were 
electrophoretically resolved on agarose and then gel-purified. Circular 
substrates containing a one repeat slip-out were made by hybridiz-
ing single-stranded circular DNA with a (CAG)47 repeat tract with 
a double-stranded linearized plasmid containing (CTG)48•(CAG)48 
repeats. Detailed procedures for making the substrates have been 
described previously (28). To prepare cell extracts for repair assay, 
U2OS Flp-In T-REx cells were induced to express GFP-FAN1-wt or 
FAN1 mutants using Dox (100 nM) for 72 hours. Cell extracts were 
prepared as described (33) from the U2OS Flp-In T-Rex, TK6, TK6 
MLH1−/−, HCT116, HCT116 complemented with chromosome 3, 
and repair-proficient HeLa cells. Slipped-strand repair reactions 
were conducted as described (32). Briefly, 22 fmol of circular slipped- 
substrates was incubated in 30 mM Hepes-KOH (pH 7.8); creatine 
kinase (100 mg/ml); 40 mM creatine phosphate; 4 mM ATP; 200 mM 
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extract at 37°C for 1 hour. Last, after releasing the repeat-containing 
fragment (EcoRI/HindIII digestion) and resolving on native 4% acryl-
amide gels, the products were electrotransferred to a membrane and 
hybridized with a radiolabeled EcoRI/HindIII fragment–containing 
17 repeats. Repair efficiency is the proportion of radio intensity 
of the repair product relative to all repeat-containing fragments 
(ImageQuant Molecular Dynamics v1.2). To analyze the effect of 
synthetic 60-mer FAN1 peptide on repair efficiency, cell extracts 
were incubated in the absence or presence of either wt or mutant 
synthetic 60-mer FAN1 peptide (GenScript) for 30 min at RT before 
starting the repair reactions.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/7/31/eabf7906/DC1
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